[1]吴小莉,吕学富,张进谷.恩替卡韦治疗慢性乙型肝炎的临床疗效及对肝功能指标的影响[J].医学信息,2024,37(12):141-143147.[doi:10.3969/j.issn.1006-1959.2024.12.032]
　WU Xiao-li,LYU Xue-fu,ZHANG Jin-gu.Clinical Efficacy of Entecavir in the Treatment of Chronic Hepatitis B and its Effect on Liver Function Indexes[J].Journal of Medical Information,2024,37(12):141-143147.[doi:10.3969/j.issn.1006-1959.2024.12.032]
点击复制

恩替卡韦治疗慢性乙型肝炎的临床疗效及对肝功能指标的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年12期
页码:
141-143147
栏目:
论著
出版日期:
2024-06-15

文章信息/Info

Title:
Clinical Efficacy of Entecavir in the Treatment of Chronic Hepatitis B and its Effect on Liver Function Indexes
文章编号:
1006-1959（2024）11-0141-04
作者:
吴小莉; 吕学富; 张进谷
（弋阳县人民医院普内科，江西 弋阳 334400）
Author(s):
WU Xiao-li; LYU Xue-fu; ZHANG Jin-gu
(Department of General Internal Medicine,Yiyang County People’s Hospital,Yiyang 334400,Jiangxi,China)
关键词:
恩替卡韦; 慢性乙型肝炎; 肝功能
Keywords:
Entecavir; Chronic hepatitis B; Liver function
分类号:
R512.6+2
DOI:
10.3969/j.issn.1006-1959.2024.12.032
文献标志码:
A
摘要:
目的 分析恩替卡韦治疗慢性乙型肝炎的临床疗效及对肝功能指标的影响。方法 选取2019年3月-2022年3月我院诊治的70例慢性乙型肝炎患者为研究对象，采用随机数字表法分为对照组和观察组，各组35例。对照组采用阿德福韦酯治疗，观察组采用恩替卡韦治疗，比较两组临床疗效、肝功能指标[血清总胆红素（TBiL）、天冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）]、HBV-DNA水平、HBeAg转阴率、不良反应发生率。结果 观察组治疗总有效率为97.14%，高于对照组的82.86%（P＜0.05）；两组治疗后TBiL、AST、ALT水平低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后HBV-DNA水平低于治疗前，且观察组低于对照组（P＜0.05）；观察组HBeAg转阴率为91.43%，高于对照组的74.29%（P＜0.05）；观察组不良反应发生率为8.57%，低于对照组的17.14%（P＜0.05）。结论 恩替卡韦治疗慢性乙型肝炎具有良好的临床疗效，可改善肝功能，提高HBeAg转阴率，降低HBV-DNA水平，且不良反应发生率低，应用安全性良好。
Abstract:
Objective To analyze the clinical efficacy of entecavir in the treatment of chronic hepatitis B and its effect on liver function indexes.Methods A total of 70 patients with chronic hepatitis B diagnosed and treated in our hospital from March 2019 to March 2022 were selected as the research objects. They were divided into control group and observation group by random number table method, with 35 patients in each group. The control group was treated with adefovir dipivoxil, and the observation group was treated with entecavir. The clinical efficacy, liver function indexes [serum total bilirubin (TBiL), aspartate aminotransferase (AST), alanine aminotransferase (ALT)], HBV-DNA level, HBeAg negative rate and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 97.14%, which was higher than 82.86% in the control group (P<0.05). After treatment, the levels of TBiL, AST and ALT in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). After treatment, the level of HBV-DNA in the two groups were lower than that before treatment, and that in the observation group was lower than that in the control group (P<0.05). The negative conversion rate of HBeAg in the observation group was 91.43%, which was higher than 74.29% in the control group (P<0.05). The incidence of adverse reactions in the observation group was 8.57%, which was lower than 17.14% in the control group (P<0.05).Conclusion Entecavir has good clinical efficacy in the treatment of chronic hepatitis B, which can improve liver function, increase HBeAg negative conversion rate, reduce HBV-DNA level, and has low incidence of adverse reactions and good application safety.

参考文献/References:

[1]余冰冰,张丽芬,陈志锦,等.慢性乙型肝炎合并肝脂肪变经恩替卡韦抗病毒治疗的效果[J].中国医药科学,2019,9(1):250-252.[2]洪晟镇,许洁.恩替卡韦与替诺福韦酯抗病毒治疗降低慢性乙型肝炎患者肝细胞癌发生风险的差异——一项韩国回顾性研究引发的思考[J].临床肝胆病杂志,2019,35(4):734-736.[3]刘肄辉,冯慧,刘莉,等.恩替卡韦对慢性乙型肝炎外周血Th9细胞动态变化的影响研究[J].中国预防医学杂志,2020,21(2):163-167.[4]孙静,朱琳,池欣,等.恩替卡韦单药与联合干扰素抗病毒治疗对慢性乙型肝炎患者肝细胞癌发生风险的影响[J].临床肝胆病杂志,2020,36(9):1975-1979.[5]梁丽,李红艺,任江波,等.长期恩替卡韦抗病毒治疗对老年慢性乙型肝炎患者肾脏功能的影响[J].中华老年医学杂志,2019,38(11):1258-1261.[6]Collaborators PO.Global prevalence,treatment,and prevention of hepatitis B virus infecti-on in 2016：a modelling study[J].Lancet Gastroenterol Hepatol,2018,3(6):383-403.[7]中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎临床治愈(功能性治愈)专家共识[J].中华肝脏病杂志,2019,27(8):594-603.[8]中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].中华肝脏病杂志,2019,27(12):938-961.[9]於裕福,陈煜,沈旭峰,等.恩替卡韦治疗男性慢性乙型病毒性肝炎对生殖功能影响的临床研究[J].中华男科学杂志,2020,26(4):326-330.[10]Ma Y,Bao X,Xiong F,et al.The effect of thymopentin add-on in hepatitis B e antigen positive chronic hepatitis B after virus suppression by peginterferon plus entecavir therapy[J].Cell Mol Biol (Noisy-le-grand),2019,65(2):75-81.[11]田贤江,赵立夫,沈跃飞,等.恩替卡韦治疗HBVDNA 低水平HBeAg阳性慢性乙型肝炎可抑制病毒复制及改善肝组织学病变[J].中华临床感染病杂志,2019,12(2):107-110,141.[12]彭菁,焦方舟,李汛,等.替诺福韦与恩替卡韦治疗HBeAg阳性慢性乙型病毒性肝炎患者临床短期疗效[J].武汉大学学报(医学版),2019,40(4):640-644.[13]陈力,吕裕斌,满景武.恩替卡韦应用于慢性乙型肝炎拉米夫定停药后再治疗中的临床观察[J].基层医学论坛,2020,24(10):1336-1337.[14]戚励,裴冬梅,杨惠,等.恩替卡韦联合美常安对乙型肝炎肝硬化患者肠道菌群及肠黏膜通透性的影响[J].实用临床医药杂志,2020,24(6):61-65.[15]徐勇,冯继红,黎志良,等.替比夫定和恩替卡韦对慢性乙型肝炎患者肾小球滤过率的影响比较[J].临床内科杂志,2018,35(3):196-197.[16]梁超,毛重山,闫宏宪.重组人干扰素α-2b联合恩替卡韦对慢性乙型肝炎患者免疫功能的影响[J].药物评价研究,2019,42(5):967-969.[17]许烂漫,朱垠,徐洁,等.恩替卡韦联合或序贯聚乙二醇干扰素α－2b对慢性乙型病毒性肝炎核苷经治患者的疗效及安全性分析[J].现代实用医学,2021,33(6):730-732.[18]郑洲松,黄宇琨,杨小丽,等.恩替卡韦序贯聚乙二醇化干扰素－α与单用恩替卡韦治疗慢性乙型肝炎的临床疗效比较：系统评价与分析[J].中国感染控制杂志,2022,21(11):1110-1117.[19]田原.比较抗乙肝病毒药物替诺福韦(TDF)与恩替卡韦(ETV)初始治疗慢性乙型肝炎(CHB)患者中疗效及安全性[J].齐齐哈尔医学院学报,2020,41(9):1128-1129. [20]彭菁,焦方舟,李汛,等.替诺福韦与恩替卡韦治疗HBeAg阳性慢性乙型病毒性肝炎患者临床短期疗效[J].武汉大学学报(医学版),2019,40(4):640-644.

相似文献/References:

[1]唐平阳.恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的 临床疗效分析[J].医学信息,2018,31(10):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
　TANG Ping-yang.Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(12):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
[2]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和 生活质量的影响研究[J].医学信息,2018,31(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
　LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2018,31(12):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[3]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
　LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Journal of Medical Information,2018,31(12):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[4]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义[J].医学信息,2018,31(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
　WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Journal of Medical Information,2018,31(12):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[5]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
　WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Journal of Medical Information,2019,32(12):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[6]马 琳,田瑞民.乙型病毒性肝炎相关晚期肝病的抗病毒治疗效果观察[J].医学信息,2019,32(07):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
　MA Lin,TIAN Rui-min.Observation on the Effect of Antiviral Therapy For Advanced Hepatopathy Associated with Viral Hepatitis B[J].Journal of Medical Information,2019,32(12):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
[7]傅 蕊,李士欣,周国强,等.床旁超声预测慢性乙型肝炎患者胃镜检查围麻醉期误吸风险的临床价值[J].医学信息,2019,32(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
　FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2019,32(12):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[8]张媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的临床特点[J].医学信息,2019,32(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
　ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2019,32(12):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[9]李嘉丽,温 静,周 甦,等.主动随访督导乙型肝炎肝硬化长期依从抗病毒的效果[J].医学信息,2019,32(10):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
　LI Jia-li,WEN Jing,ZHOU Su,et al.Active Follow-up to Monitor the Long-term Compliance with Antiviral Effects of Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(12):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
[10]陈新华.拉米夫定联合恩替卡韦治疗乙型肝炎相关肝硬化的 长期疗效与安全性分析[J].医学信息,2019,32(18):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
　CHEN Xin-hua.Long-term Efficacy and Safety of Lamivudine Combined with Entecavir in the Treatment of Hepatitis B-related Cirrhosis[J].Journal of Medical Information,2019,32(12):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
[11]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Journal of Medical Information,2018,31(12):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[12]张 瑜,路青华,曹海芳,等.聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响[J].医学信息,2021,34(17):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]
　ZHANG Yu,LU Qing-hua,CAO Hai-fang,et al.Effect of Polyethylene Glycol Interferon,PEG-IFN Combined with Entecavir on Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2021,34(12):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]

更新日期/Last Update: 1900-01-01